|1.||Rames, Alexis: 1 article (10/2002)|
|2.||Lazabemide in Smoking Cessation Study Investigators: 1 article (10/2002)|
|3.||Lagrue, Gilbert: 1 article (10/2002)|
|4.||Lancrenon, Sylvie: 1 article (10/2002)|
|5.||Aubin, Henri-Jean: 1 article (10/2002)|
|6.||Pedarriosse, Anne-Marie: 1 article (10/2002)|
|7.||Berlin, Ivan: 1 article (10/2002)|
|1.||Parkinson Disease (Parkinson's Disease)
04/01/1994 - "No significant improvement in the clinical features of Parkinson's disease was found after 4 weeks of lazabemide treatment. "
11/01/1999 - "To evaluate whether lazabemide has proarrhythmic or hypotensive potency in Parkinson's disease (PD), we conducted an 8-week, double-blind, placcbo-controlled, parallel group study with use of 24-hour ambulatory electrocardiographic (ECG) monitoring. "
07/01/1996 - "We previously found lazabemide to be safe and well tolerated at dosages of up to 400 mg/day during a 6-week study of 201 patients with early untreated Parkinson's disease (PD). "
04/01/1993 - "A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. "
07/01/1996 - "Effect of lazabemide on the progression of disability in early Parkinson's disease. "
|2.||Cardiac Arrhythmias (Arrythmia)
|3.||Alzheimer Disease (Alzheimer's Disease)
|5.||Parkinsonian Disorders (Parkinsonism)
|1.||Monoamine Oxidase (MAO)
|2.||Levodopa (L Dopa)
|4.||Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)